The Need for a New Approach in Treating Psychiatric Disease

EpiVario was founded by epigeneticists at the University of Pennsylvania with the goal of developing products to provide novel treatments for many unmet needs in psychiatric disease. Join their CEO, Thomas Kim, for a frank discussion about the work EpiVario is doing.EpiVario, an early-stage drug discovery and development company,has raised $445K in a seed round to support the development of a new treatment for a wide range of memory-related psychiatric disorders at the source, including PTSD, Alzheimer’s, and alcohol and drug addiction. Founded by University of Pennsylvania epigeneticists, the Company’s approach is different than anything currently on the market. It works by targeting the non-essential ACSS2 gene to prevent the process of negative memory formation or reconsolidation, a key contributor to PTSD and other memory-related conditions. The funds will be used to hire additional research staff and support the first phase of preclinical research milestones.There are currently 26 million people living with PTSD in the US and 296 million worldwide. It’s estimated that 8% of the U.S. population experiences PTSD at some point during their lifetime. The U.S. government spends an estimated $2 billion annually to help treat PTSD in the veteran population. The global market for PTSD treatment is expected to reach nearly $10.7 billion by 2026.www.epivario.comBecome a supporter of this podcast: https://www.spreaker.com/podcast/mental-health-news-radio--3082057/support.